OBJECTIVES: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli have emerged as significant causes of community-onset disease. We sought to identify risk factors for acquiring community-onset ESBL-producing E. coli. METHODS: Prospective, population-based surveillance for ESBL-producing E. coli was performed in the Calgary Health Region (population 1.2 million), Canada during a two-year period. RESULTS: 247 patients were identified; 177 (72%; 7.6 per 100,000/year) were community acquired, and 70 (28%; 3.0 per 100,000/year) were healthcare associated. The acquisition risk increased with advancing age. Females were at higher risk as compared to males [relative risk (RR) 4.3; 95% confidence interval (CI), 3.1-6.1] as were urban as compared to rural residents (RR 2.2; 95% CI, 1.4-3.6). A number of co-morbidities increased risk (RR; 95% CI) including requirement for hemodialysis (56.3; 15.1-147.4), urinary incontinence (21.7; 15.0-30.9), cancer (11.1; 7.0-17.0), heart disease (6.5; 4.3-9.7), and diabetes (4.4; 2.6-7.1). Overseas travel overall increased the risk (5.7; 4.1-7.8) and was highest in travelers to India (145.6; 77.7-252.1), the Middle East (18.1; 8.1-35.2), and Africa (7.7; 2.8-17.2). CONCLUSIONS: Advancing age, female gender, co-morbid medical conditions, and foreign travel are important risk factors for developing community-onset ESBL-producing E. coli infections in our region. Emergence of anti-microbial-resistant pathogens is a global concern.
OBJECTIVES:Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli have emerged as significant causes of community-onset disease. We sought to identify risk factors for acquiring community-onset ESBL-producing E. coli. METHODS: Prospective, population-based surveillance for ESBL-producing E. coli was performed in the Calgary Health Region (population 1.2 million), Canada during a two-year period. RESULTS: 247 patients were identified; 177 (72%; 7.6 per 100,000/year) were community acquired, and 70 (28%; 3.0 per 100,000/year) were healthcare associated. The acquisition risk increased with advancing age. Females were at higher risk as compared to males [relative risk (RR) 4.3; 95% confidence interval (CI), 3.1-6.1] as were urban as compared to rural residents (RR 2.2; 95% CI, 1.4-3.6). A number of co-morbidities increased risk (RR; 95% CI) including requirement for hemodialysis (56.3; 15.1-147.4), urinary incontinence (21.7; 15.0-30.9), cancer (11.1; 7.0-17.0), heart disease (6.5; 4.3-9.7), and diabetes (4.4; 2.6-7.1). Overseas travel overall increased the risk (5.7; 4.1-7.8) and was highest in travelers to India (145.6; 77.7-252.1), the Middle East (18.1; 8.1-35.2), and Africa (7.7; 2.8-17.2). CONCLUSIONS: Advancing age, female gender, co-morbid medical conditions, and foreign travel are important risk factors for developing community-onset ESBL-producing E. coli infections in our region. Emergence of anti-microbial-resistant pathogens is a global concern.
Authors: Mario Tumbarello; Enrico Maria Trecarichi; Matteo Bassetti; Francesco Giuseppe De Rosa; Teresa Spanu; Eugenia Di Meco; Angela Raffaella Losito; Andrea Parisini; Nicole Pagani; Roberto Cauda Journal: Antimicrob Agents Chemother Date: 2011-05-02 Impact factor: 5.191
Authors: D K Pomakova; C-B Hsiao; J M Beanan; R Olson; U MacDonald; Y Keynan; T A Russo Journal: Eur J Clin Microbiol Infect Dis Date: 2011-09-15 Impact factor: 3.267
Authors: Latania K Logan; Rachel L Medernach; Jared R Rispens; Steven H Marshall; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Xiaotian Zheng; Nadia K Qureshi; Sreenivas Konda; Mary K Hayden; Robert A Weinstein; Robert A Bonomo Journal: Pediatr Infect Dis J Date: 2019-06 Impact factor: 2.129
Authors: Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson Journal: Antimicrob Agents Chemother Date: 2014-01-27 Impact factor: 5.191
Authors: Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten Journal: Antimicrob Agents Chemother Date: 2013-04-22 Impact factor: 5.191